#1 Clinical Trials Search in Europe

Gs-5245

Obeldesivir, also known as GS-5245, is an investigational drug being studied for the treatment of COVID-19. This article summarizes key information from clinical trials evaluating Obeldesivir in different patient populations, including children, adolescents, and adults with varying levels of kidney function. The trials aim to assess the safety, effectiveness, and how the body processes this potential new treatment for COVID-19.

Table of Contents

What is GS-5245 (Obeldesivir)?

GS-5245, also known as Obeldesivir (ODV), is a new antiviral medication being developed to treat COVID-19[1]. It is classified as a small molecule drug, which means it is a low molecular weight compound that can easily enter cells to perform its function[1].

How does GS-5245 work?

While the exact mechanism of action is not fully described in the provided information, GS-5245 is designed to combat the SARS-CoV-2 virus, which causes COVID-19. It is metabolized in the body to form GS-441524, which is likely the active form of the drug that fights the virus[1].

Clinical Trials

GS-5245 is currently being studied in several clinical trials:

  • A Phase 2/3 study in children and adolescents with COVID-19[1]
  • A Phase 1 study in adults with normal kidney function and reduced kidney function[2]

These trials aim to evaluate the safety, effectiveness, and how the body processes the drug (pharmacokinetics) in different patient populations.

Potential Benefits

The clinical trials are investigating several potential benefits of GS-5245, including:

  • Reducing the time it takes for COVID-19 symptoms to improve[1]
  • Decreasing the amount of virus in the body[1]
  • Reducing the need for supplemental oxygen[1]
  • Lowering the risk of hospitalization or death due to COVID-19[1]

Safety and Side Effects

The safety of GS-5245 is being closely monitored in the clinical trials. Researchers are tracking any side effects (adverse events) and changes in laboratory test results that occur during treatment[1][2]. As with any new medication, it’s important to understand that the full safety profile is still being established.

Administration

GS-5245 is being developed as an oral medication in the form of film-coated tablets. It comes in two strengths: 175 mg and 350 mg[1][2]. The exact dosing regimen may vary depending on factors such as age, weight, and kidney function.

Ongoing Research

Current research is focusing on several key areas:

  • How the drug works in children and adolescents with COVID-19, including those with underlying health conditions that put them at higher risk[1]
  • How kidney function affects the way the body processes the drug[2]
  • The drug’s effectiveness against different variants of the SARS-CoV-2 virus
  • Long-term safety and efficacy data

It’s important to note that GS-5245 is still an investigational drug, which means it has not yet been approved by regulatory agencies for general use. More research is needed to fully understand its benefits and risks in treating COVID-19.

Aspect Details
Drug Name Obeldesivir (GS-5245)
Condition Studied COVID-19
Study Populations Children, adolescents, adults with normal and impaired kidney function
Main Objectives Evaluate safety, pharmacokinetics, and efficacy
Administration Oral tablets (175 mg and 350 mg)
Key Measurements Drug concentrations in blood and urine, symptom alleviation, viral load changes, safety assessments
Special Considerations Impact of kidney function on drug behavior, palatability in pediatric patients

FAQ

  • What is Obeldesivir (GS-5245)? Obeldesivir, also known as GS-5245, is an investigational antiviral drug being studied as a potential treatment for COVID-19. It is taken orally in the form of film-coated tablets.
  • Who is being included in these clinical trials? The trials are including a wide range of participants, from newborns to adults. One study focuses on children and adolescents with COVID-19, while another study includes adults with normal kidney function and various levels of kidney impairment.
  • What are the main goals of these clinical trials? The main goals are to evaluate the safety of Obeldesivir, how the body processes the drug (pharmacokinetics), and its effectiveness in treating COVID-19. The studies also aim to assess how kidney function may affect the drug's behavior in the body.
  • How is Obeldesivir administered in these trials? Obeldesivir is given orally as film-coated tablets. The exact dosage varies depending on the specific trial and participant group, but it can range from 175 mg to 350 mg tablets.
  • What are some of the key things being measured in these trials? The trials are measuring several important factors, including the concentration of the drug in the blood and urine, how quickly symptoms improve, changes in the amount of virus in the body, and any side effects or safety concerns that may arise during treatment.

Ongoing Clinical Trials on Gs-5245

  • Study on How Kidney Function Affects the Drug GS-5245 in Patients With Normal and Impaired Kidney Function

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of GS-5245 for Treating COVID-19 in Children and Adolescents

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Hungary Italy Poland Spain

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Efficacy: How well a treatment works to produce the desired effect, such as reducing symptoms or fighting a virus.
  • Renal impairment: A condition where the kidneys are not working as well as they should, which can affect how drugs are processed in the body.
  • eGFR: Estimated Glomerular Filtration Rate, a measure of kidney function used to determine the level of kidney impairment.
  • AUC: Area Under the Curve, a measure of the total exposure to a drug in the body over time.
  • Cmax: The maximum concentration of a drug reached in the blood after dosing.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the study treatment.
  • SARS-CoV-2: The virus that causes COVID-19.
  • Antiviral: A type of medication that helps fight viral infections by interfering with the virus's ability to spread or reproduce.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being given.

References

  1. http://clinicaltrials.eu/trial/study-of-gs-5245-for-treating-covid-19-in-children-and-adolescents/
  2. http://clinicaltrials.eu/trial-id/2023-504780-17-00